Patent ID: 8420884

Claim:
A method for screening at least one compound to determine ability to treat an oncological disorder regulated through a tumor-inducing pathway, the method comprising: administering the compound to transgenic mice as an animal disease model, wherein the transgenic mice display pathology symptoms that correspond to the oncological disorder Glioblastoma multiforme in a human, wherein the genome of the transgenic mice comprises a regulatable transgene of human origin of a wild type epidermal growth factor receptor (EGFR WT ) and a mutant form vIII (EGFR vIII ) associated with tumor formation (EGFR WT / EGFR vIII ) or two copies of transgene EGFR vIII (EGFR vIII /EGFR vIII ), wherein expression of the transgene is associated with tumor formation, and the genome of the transgenic mice further comprises mutations in genes encoding Phosphatase and Tensin homolog detected on chromosome Ten (PTEN), p16Ink4a, and p19Arf as regulatable genes, wherein the disease pathology symptoms are induced using a-site-specific recombination system to induce expression of the transgene associated with tumor formation and negatively regulate or eliminate the gene expression of pTEN, p16Ink4a and p19Arf genes; analyzing tumors appearing in the transgenic mice administered the compound; and, comparing appearance and amount of tumors in the transgenic mice administered the compound and in control transgenic mice not administered the compound, wherein a decrease in tumors in the transgenic mice administered the compound compared to control transgenic mice is an indication that the compound treats the oncological disorder.